PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
5.43
Current Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 2.39. Joel Greenblatt would see extra liquidity as a cushion for downturns.
4.43
Quick Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 1.84. Joel Greenblatt would see a superior short-term safety net.
3.26
Cash Ratio above 1.5x Drug Manufacturers - Specialty & Generic median of 0.86. Joel Greenblatt might see a strategic advantage in crisis periods.
-1.23
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
-4.71
Negative short-term coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.